“[Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy]”, FE, vol. 24, no. 1, Dec. 2023, doi: 10.7175/fe.v24i1.1548.